Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 15, 2016 03:00 ET | Source: Novartis Pharma AG

Novartis lance « FreeNovation », un concept de promotion de la recherche unique en Suisse

« FreeNovation » est un concept de promotion innovant de la Fondation Novartis pour la Recherche. Il s'adresse aux chercheurs en Suisse désireux de traiter les questions majeures relevant de la...
March 15, 2016 03:00 ET | Source: Novartis Pharma AG

Novartis lanciert «FreeNovation», ein in der Schweiz bislang einzigartiges Konzept zur Forschungsförderung

«FreeNovation» steht für ein neuartiges Förderkonzept der Novartis Forschungsstiftung. Es richtet sich an Forschende in der Schweiz, die mit unkonventionellen Ideen wichtige Fragen der Biomedizin...
March 05, 2016 12:00 ET | Source: Novartis Pharma AG

Novartis' Cosentyx superior to Stelara in delivering long-lasting skin clearance (PASI 90) for psoriasis patients at 52 weeks

New data at AAD 2016 shows Cosentyx® is significantly more efficacious than Stelara in sustaining skin clearance (PASI 90 to PASI 100) at 52 weeks[1] Cosentyx delivered and sustained skin...
February 26, 2016 14:43 ET | Source: Novartis Pharma AG

FDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET)

In advanced progressive, nonfunctional NET, Afinitor is the first approved treatment for patients with lung NET and the first oral therapy for GI NET Approval helps fulfill unmet need as...
February 23, 2016 07:19 ET | Source: Novartis Pharma AG

Novartis Aktionäre genehmigen alle Anträge des Verwaltungsrats

Aktionäre genehmigen für 2015 die 19. Dividendenerhöhung in Folge auf CHF 2,70 pro Aktie (+4%) Dr. Jörg Reinhardt als Präsident des Novartis Verwaltungsrats ebenso wie alle weiteren Mitglieder des...
February 23, 2016 07:19 ET | Source: Novartis Pharma AG

Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administration

Les actionnaires approuvent la 19e hausse consécutive du dividende, à CHF 2,70 par action (+4%) au titre de l'exercice 2015. Le Dr Joerg Reinhardt est confirmé par les actionnaires dans ses fonctions...
February 23, 2016 07:19 ET | Source: Novartis Pharma AG

Novartis shareholders approve all resolutions proposed by Board of Directors

Shareholders approve 19th consecutive dividend increase to CHF 2.70 (+4%) per share for 2015 Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Directors as well as all...
February 19, 2016 01:15 ET | Source: Novartis Pharma AG

Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)

PKC412 (midostaurin) significantly improved overall survival of adult patients eligible to receive standard induction and consolidation chemotherapy AML has the lowest survival rate of all adult...
February 18, 2016 01:00 ET | Source: Novartis Pharma AG

Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.

Acquisition to add minimally-invasive glaucoma surgery (MIGS) device to pipeline, expanding Alcon's surgical presence in a new category to treat glaucoma The goal of MIGS is to reduce or...
February 12, 2016 01:00 ET | Source: Novartis Pharma AG

Sandoz strengthens its biosimilars portfolio with acquisition of Pfizer's biosimilar infliximab in EEA

Sandoz acquires rights to PF-06438179 (biosimilar infliximab) in the European Economic Area (EEA)* Sandoz plans to complete Phase III development program and file for registration in the EU ...